Radiopharmaceutical Theranostics Market Report 2026

The radiopharmaceutical theranostics market size has grown rapidly in recent years. It will grow from $3.27 billion in 2025 to $3.76 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to expansion of nuclear medicine applications, increasing cancer incidence rates, advancements in radioisotope production techniques, growth in diagnostic imaging integration, early adoption of theranostic treatment models.

The radiopharmaceutical theranostics market size is expected to see rapid growth in the next few years. It will grow to $6.64 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to growing investments in precision oncology, rising demand for personalized radiopharmaceutical therapies, expansion of clinical trials for novel isotopes, increasing collaboration between diagnostics and therapeutics, ongoing innovation in isotope supply chains. Major trends in the forecast period include increasing development of targeted theranostic radiopharmaceuticals, rising use of pet-based personalized therapies, growing adoption of alpha and beta emitters in oncology, expansion of cyclotron-based isotope production, enhanced focus on precision oncology applications.

The increasing incidence of cancer is expected to drive the growth of the radiopharmaceutical theranostics market in the coming years. Cancer refers to a disease characterized by abnormal and uncontrolled cell growth that can invade surrounding tissues and spread to other parts of the body. Radiopharmaceutical theranostics supports cancer care by enabling targeted and personalized treatment approaches that combine diagnosis and therapy. For instance, in 2023, according to the American Cancer Society, a US-based voluntary health organization, approximately 1.9 million new cancer cases were projected to be diagnosed in the United States, with about 609,820 cancer-related deaths expected. In addition, 88% of diagnosed individuals were estimated to be aged 50 years or older. Therefore, the rising incidence of cancer is contributing to the expansion of the radiopharmaceutical theranostics market.

Major companies operating in the radiopharmaceutical theranostics market are focusing on the development of advanced theranostic solutions aimed at cancer treatment. Theranostic approaches are increasingly being explored to provide targeted therapies and diagnostic solutions, particularly for patients with limited treatment options such as those with cancer. For example, in November 2023, GE HealthCare Technologies Inc., a US-based medical technology company, launched new theranostics solutions for cancer. Theranostics represents an emerging area of precision medicine that integrates therapeutic agents with imaging technologies to identify and selectively target cancer cells for treatment.

In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company specializing in radiopharmaceutical products, acquired Pharma15 Corporation for $4 million. Through this acquisition, Radiopharm aims to advance the development of next-generation radiopharmaceuticals for prostate cancer treatment, with a focus on improving upon existing PSMA-based therapies and delivering innovative solutions for patients. Pharma15 Corporation is a US-based pharmaceutical company focused on developing radio-immuno-theranostics platforms and related pharmaceutical products.

Major companies operating in the radiopharmaceutical theranostics market are Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.

North America was the largest region in the radiopharmaceutical theranostics market in 2025. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiopharmaceutical theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the radiopharmaceutical theranostics market by increasing costs of imported radioisotopes, cyclotron components, nuclear reactor materials, specialized synthesis equipment, and radiation shielding systems. Hospitals and research centers in North America and Europe are most affected due to reliance on global isotope supply chains, while Asia-Pacific faces cost pressures on production scalability. These tariffs are increasing treatment costs and constraining supply reliability. However, they are also encouraging domestic isotope production, regional cyclotron investments, and localized manufacturing of theranostic radiopharmaceuticals.

The radiopharmaceutical theranostics market research report is one of a series of new reports that provides radiopharmaceutical theranostics market statistics, including radiopharmaceutical theranostics industry global market size, regional shares, competitors with a radiopharmaceutical theranostics market share, detailed radiopharmaceutical theranostics market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceutical theranostics industry. This radiopharmaceutical theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Radiopharmaceutical theranostics is an integrated medical approach that combines diagnostics and therapeutics using radiopharmaceutical agents. This approach enables disease diagnosis, targeted treatment, and personalized patient management within a single framework.

The primary product types in radiopharmaceutical theranostics include alpha emitters, beta emitters, and positron emission tomography tracers. Alpha emitters are radioactive substances that release alpha particles, which are high-energy particles composed of two protons and two neutrons. These radiopharmaceuticals are produced using sources such as nuclear reactors and cyclotrons, and involve radioisotopes including technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18, yttrium-90, lutetium-177, copper-67, copper-64, and others. They are used across indications such as oncology, cardiology, neurology, and other areas, and are utilized by end users including hospitals, diagnostic imaging centers, academic and research institutes, and others.

The radiopharmaceutical theranostics market includes revenues earned by providing genetic testing, targeted therapy services, contract development, and manufacturing services, consultation and interpretation, and personalized therapeutic interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.